LGNDLGNDHealthcare · Biotechnology

LGND Stock Forecast: Ligand Pharmaceuticals, Inc. Price Predictions for 2026-2027

Last close, 17 Nov 2026
$294
−2.62% on the day

The 11 Wall Street analysts covering Ligand Pharmaceuticals, Inc. hold a median 12-month price target of $350 — +19.1% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 68 of 100 as at 16 Nov 2026 — in the upper half.

Market cap
$6.2B
Ticker Nerd rank
68/ 100
Median analyst target
$350
Analysts covering
11
Revenue$63.7M+33.7% y/y
Operating income$8.6M
Net income$48.5M
Free cash flow$21.4M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−6.5%
1M
−0.6%
YTD
+55.4%
1Y
+45.9%
From 52W high
−9.0%
From 52W low
+61.7%
$182
$323
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

LGND stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Ligand Pharmaceuticals, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 16 Nov 2026
68/ 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Momentum
98
Quality
84
Volatility
80
Revisions
74
Value
74
Growth
51
Accruals
33
Size
20
Issuance
15

Momentum (98): The shares have been drifting up relative to others.

Issuance (15): The company has been issuing shares or taking on financing, diluting existing holders.

Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.

Wall Street

LGND stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on LGND, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$200$250$300$350$400Jan 26Apr 26Jul 26Oct 26LGNDHigh $406Median $350Low $335

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says11 analysts
11 Buy0 Hold0 Sell
Low $335Median $350High $406

The green dot is the last close — the median target sits +19.1% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 7 moved their price target up and 0 moved it down.

DateFirmActionRatingTarget
11 Nov 2026BarclaysMaintainsOverweight$345 → $350
5 Nov 2026CitigroupMaintainsBuy$397 → $402
30 Oct 2026RBC CapitalMaintainsOutperform—
30 Oct 2026RBC CapitalMaintainsOutperform$345 → $357
25 Sept 2026BarclaysInitiatesOverweight—
25 Sept 2026BarclaysInitiatesOverweight$345
24 Sept 2026HC Wainwright & Co.ReiteratesBuy—
24 Sept 2026HC Wainwright & Co.ReiteratesBuy$358
23 Sept 2026CitigroupMaintainsBuy—
23 Sept 2026CitigroupMaintainsBuy$390 → $397
14 Aug 2026Leerink PartnersInitiatesOutperform$330
14 Aug 2026Leerink PartnersInitiatesOutperform—
7 Aug 2026RBC CapitalMaintainsOutperform$340 → $345
7 Aug 2026RBC CapitalMaintainsOutperform—
6 Aug 2026HC Wainwright & Co.MaintainsBuy$289 → $358
6 Aug 2026HC Wainwright & Co.MaintainsBuy—
3 Aug 2026OppenheimerReiteratesOutperform—
3 Aug 2026OppenheimerReiteratesOutperform$285 → $326
21 July 2026CitigroupReinstatesBuy$387
15 July 2026RBC CapitalMaintainsOutperform—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

LGND appears in the Radar on the weeks it earns a place.

  • Market Radar, every Monday: the week's biggest rank moves across ~4,600 US stocks, and the reason for each.
  • The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.

Free. Unsubscribe any time. Privacy

The AI build-out map
PDF
  • AI cloud capacity

    MSFTAMZNGOOGLORCL

  • AI chips

    NVDAAVGOAMDMU

  • AI networking and servers

    ANETDELLLITECRDO

  • Data centre power

    VRTCEGGEVVST

Performance

LGND vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 17 Nov 2026, Ligand Pharmaceuticals, Inc. returned +45.9% against +11.2% for the S&P 500, dividends included.

LGND vs S&P 500, last 12 monthsTotal return, rebased to 100
80100120140160Jan 26Apr 26Jul 26Oct 26LGNDS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

LGND analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingThis fiscal year
EPS revision, 90 days
+2.8%
Analysts raising
5
Analysts cutting
0
Fundamentals

Ligand Pharmaceuticals, Inc. (LGND) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
127.1×

Cheaper than 5% of US stocks

Price / sales
24.3×

Cheaper than 7% of US stocks

Price / book
6.4×

Cheaper than 14% of US stocks

EV / EBITDA
96.3×

Cheaper than 2% of US stocks

Growth & margins
Revenue growth (YoY)
−31.8%

Higher than 8% of US stocks

Earnings growth (YoY)
33.7%

Higher than 68% of US stocks

Gross margin
95.0%

Higher than 98% of US stocks

Operating margin
14.4%

Higher than 73% of US stocks

Net margin
20.3%

Higher than 82% of US stocks

Returns & dividend
Return on equity
5.4%

Higher than 53% of US stocks

Return on assets
1.2%

Higher than 51% of US stocks

Dividend yield
0.0%

Higher than 1% of US dividend payers

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Ligand Pharmaceuticals, Inc. (LGND) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Ligand Pharmaceuticals, Inc. has a market value of $6.2B and an enterprise value of $6.9B.

  • Revenue in the twelve months to 30 June 2026: $290.5M. The latest quarter shrank 31.8% year on year.

  • Net income over the same four quarters: $197.2M, a 67.9% net margin.

  • Diluted earnings per share, trailing twelve months: $9.35.

  • Free cash flow in the twelve months to 30 June 2026: $119.8M.

  • Shares outstanding: 19.9M.

  • Trailing P/E: 127.1×; forward P/E: 25.8× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Forward dividend yield: 0.00%, paying out 0% of earnings.

  • Ligand Pharmaceuticals, Inc. employs 47 people — $6.2M of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 16 Nov 2026

Data provided by Twelve Data

Peers

LGND vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
LGNDLigand Pharmaceuticals, Inc.$6.2B68
MIRMMirum Pharmaceuticals, Inc.$5.9B56
CAICaris Life Sciences, Inc.$5.9B25
ARWRArrowhead Pharmaceuticals, Inc.$6.2B41
IBRXImmunityBio, Inc.$6.3B40
ORKAOruka Therapeutics, Inc.$6.6B37
KODKodiak Sciences, Inc.$6.6B59

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Ligand Pharmaceuticals, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest LGND news & analysis

Ligand Pharmaceuticals: Filspari And XOMA Strengthen The Case For A Buy

Seeking Alpha · 4 Nov 2026positive

Seeking Alpha assigns Ligand Pharmaceuticals a Buy rating, citing 85% year-over-year royalty growth from Filspari and the addition of a new FSGS indication. It also points to XOMA’s $12.3 million Q3 royalty contribution and pipeline as sources of revenue diversification and potential catalysts.

Why it matters — The item highlights Filspari’s royalty growth and XOMA’s contribution as factors shaping Ligand’s revenue mix and future prospects.

Ligand Pharmaceuticals Incorporated (LGND) Q3 2026 Earnings Call Transcript

Seeking Alpha · 30 Oct 2026neutral

Seeking Alpha published the transcript of Ligand Pharmaceuticals’ third-quarter 2026 earnings call, held October 29, 2026. The excerpt lists company and call participants but provides no discussion of results or business updates.

Why it matters — The transcript may be relevant to LGND watchers seeking management commentary, though this excerpt contains no substantive earnings details.

What Ligand Pharmaceuticals (LGND) Said on Its Q3 Earnings Call

MarketBeat · 29 Oct 2026positive

Ligand reported third-quarter royalty revenue growth of 51% year over year to approximately $70 million, driven by Filspari, Ohtuvayre and commercial assets acquired in its July purchase of XOMA Royalty. It raised its full-year adjusted diluted earnings-per-share outlook while maintaining revenue guidance.

Why it matters — The update highlights royalty revenue growth and a higher adjusted earnings outlook, while the company’s revenue guidance remained unchanged.

Ligand Reports Third Quarter 2026 Financial Results

GlobeNewsWire · 29 Oct 2026positive

Ligand reported third-quarter 2026 royalty revenue of $70.3 million, up 51% year over year. It raised its full-year adjusted diluted EPS guidance to $9.50–$9.75 from $9.00–$9.50 and reaffirmed revenue guidance.

Why it matters — The report combines year-over-year royalty growth with higher adjusted EPS guidance, while leaving revenue guidance unchanged.

Ligand to Participate in November Investor Conferences

GlobeNewsWire · 27 Oct 2026neutral

Ligand Pharmaceuticals announced that its senior management team will participate in the UBS Global Healthcare Conference in November.

Why it matters — LGND watchers may note the upcoming conference as an opportunity for management to engage with investors.

FAQ

Frequently asked questions about LGND stock

What is the LGND stock price forecast for 2026-2027?

The 11 Wall Street analysts covering Ligand Pharmaceuticals, Inc. have a median 12-month price target of $350, with estimates ranging from $335 to $406. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is LGND stock a buy right now?

Of the 11 analysts covering Ligand Pharmaceuticals, Inc., 11 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Ligand Pharmaceuticals, Inc. 68 out of 100 across roughly 4,600 US stocks as at 16 Nov 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank LGND?

As at 16 Nov 2026, Ligand Pharmaceuticals, Inc. ranks 68 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Momentum (98 of 100).

Will LGND stock go up?

No one can know that. What the data says: the median 12-month target from 11 analysts implies +19.1% from the last close, and Ticker Nerd's factor model ranks Ligand Pharmaceuticals, Inc. 68 out of 100 as at 16 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the LGND stock forecast for 2030?

No analyst covering Ligand Pharmaceuticals, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for LGND are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $335 to $406 over the next 12 months.

How has LGND stock performed over the past year?

Ligand Pharmaceuticals, Inc. returned +45.9% over the 12 months to 17 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Ligand Pharmaceuticals, Inc. do?

Ligand Pharmaceuticals Incorporated is a biopharmaceutical company that focuses on developing and licensing technologies and assets that support the discovery and development of medicines. Ligand Pharmaceuticals Incorporated operates a royalty-driven business model, partnering with other biopharmaceutical companies to finance and advance late-stage clinical programs while also managing a broad portfolio of royalty interests.

What is the latest news on LGND?

The most recent item we track (Seeking Alpha, 4 Nov 2026): "Ligand Pharmaceuticals: Filspari And XOMA Strengthen The Case For A Buy". Seeking Alpha assigns Ligand Pharmaceuticals a Buy rating, citing 85% year-over-year royalty growth from Filspari and the addition of a new FSGS indication. It also points to XOMA’s $12.3 million Q3 royalty contribution and pipeline as sources of revenue diversification and potential catalysts.

Company

About Ligand Pharmaceuticals, Inc.

Ligand Pharmaceuticals Incorporated is a biopharmaceutical company that focuses on developing and licensing technologies and assets that support the discovery and development of medicines. Ligand Pharmaceuticals Incorporated operates a royalty-driven business model, partnering with other biopharmaceutical companies to finance and advance late-stage clinical programs while also managing a broad portfolio of royalty interests. Its current portfolio spans commercial, clinical, and preclinical-stage assets across multiple therapeutic areas, including infectious diseases, oncology, respiratory conditions, kidney disease, and rare diseases. The company also works through technology licensing and asset acquisition activities to expand the range of medicines connected to its platform. Based in Jupiter, Florida, Ligand Pharmaceuticals Incorporated plays a specialized role in the life sciences market by providing capital, expertise, and royalty management across a diversified set of partnered drug programs.

CEO Mr. Todd C. Davis Ph.D. · 47 employees · United States · https://www.ligand.com